Neoleukin Therapeutics, Inc. (NLTX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Neoleukin Therapeutics, Inc. (NLTX)
Go deeper and ask any question about NLTX
Company Performance
Current Price
as of Sep 13, 2024$41.95
P/E Ratio
N/A
Market Cap
$544.9M
Description
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Metrics
Overview
- HQSeattle, WA
- SectorHealth Technology
- IndustryBiotechnology
- TickerNLTX
- Price$41.95+3.94%
Trading Information
- Market Cap$544.90M
- Float79.14%
- Average Daily Volume (1m)76,273
- Average Daily Volume (3m)132,136
- EPS-$3.71
Company
- Revenue$0.93M
- Rev Growth (1yr)N/A
- Net Income-$18.49M
- Gross Margin11.68%
- EBITDA Margin-2,088.32%
- EBITDA-$19.32M
- EV$476.38M
- EV/Revenue515.01
- P/EN/A
- P/S768.32
Documents
SEC Filings
Factset